Article Figures & Data
Figures
- Fig. 1.
Kaplan-Meier survival curves. Survival curves were constructed using the Kaplan-Meier classical method, and they included the 227 patients. Cumulative survival is expressed as a percentage, and survival is expressed in months as described in“ Materials and Methods.”
- Fig. 2.
Sequencing of Ki-RAS in adenocarcinoma. Sequencing of Ki-RAS cloned symmetric PCR products [panel 1, normal codon 12, GTT (glycine); panel 2, mutated codon 12, GTG (cysteine); panel 3, mutated codon 12, GTC (valine)] and sequencing of Ki-RAS asymmetric PCR products [panel 4, codon 8 mutation (TCC to TAC) + codon 12 cysteine mutation; panel 5, codon 14 mutation from GCT to GAT; and panel 6, codon 15 mutation from TAC to TAT].
Tables
- Table 1
Population characteristics
Tumor staging: pTNM I II IIIA IIIB + IV All stages Squamous cell carcinoma Malea 42 24 43 17 126 Femalea 3 1 0 2 6 Age (yr) 62.96 ± 9.30 60.16 ± 9.50 61.98 ± 9.65 60.74 ± 9.31 61.79 ± 9.41 Tobacco (pack-yr) 45.18 ± 22.35 40.32 ± 20.83 43.12 ± 20.83 37.47 ± 21.58 42.55 ± 20.49 Nonrelated deathsa 11 5 11 2 29 (21.97%) Relapsesa 10 8 26 11 55 (41.67%) Survivorsa 24 12 6 6 48 (36.36%) Length of survival (mo) 41.55 ± 27.62 38.68 ± 29.52 27.71 ± 27.95 21.95 ± 23 33.68 ± 28.23 Adenocarcinoma Malea 39 9 22 13 83 Femalea 7 2 2 1 12 Age (yr) 63.57 ± 9.26 58.45 ± 8.13 58.50 ± 9.45 54.50 ± 9.03 60.36 ± 9.00 Tobacco (pack-yr) 40.07 ± 25.69 30.64 ± 21.91 37.35 ± 13.03 34.29 ± 19.92 37.44 ± 21.84 Nonrelated deathsa 6 2 5 1 14 (14.73%) Relapsesa 24 6 18 12 60 (63.16%) Survivorsa 16 3 1 1 21 (22.11%) Length of survival (mo) 35.5 ± 24.90 33.55 ± 26.32 19.64 ± 18.95 28.64 ± 29.48 30.26 ± 24.95 -
a In number of patients.
-
- Table 2
Squamous cell lung carcinoma: predicative significance of each parameter
Tumor cell staining Covariates P Death from other causes Survivors Relapses Survival (mo) No. of patients Differentiationa + 16 31 30 39.90 ± 30.50 77 0.30 − 13 17 25 24.97 ± 22.16 55 Bcl-2b + 13 12 14 30.02 ± 28.04 39 0.99 − 16 35 41 34.61 ± 27.86 92 ABH antigensb + 16 27 25 37.41 ± 29.55 68 0.074 − 13 21 30 29.71 ± 26.40 64 p53b + 19 34 38 34.73 ± 28.45 91 0.66 − 10 14 17 31.34 ± 27.93 41 Pan-Rasb + 2 8 6 39.28 ± 26.78 16 0.38 − 27 40 49 32.91 ± 28.45 116 C-erbB2b + 7 12 16 32.45 ± 27.32 35 0.83 − 22 36 39 34.12 ± 28.67 97 Blood types O 9 24 22 38.71 ± 26.89 55 0.20 B 4 6 8 37.22 ± 29.97 18 0.74 A 15 14 25 25.23 ± 26.46 54 0.08 AB 1 4 0 56.80 ± 34.79 5 0.056 Sex Male 28 53 45 33.70 ± 28.4 126 0.66 Female 1 3 2 34.00 ± 27.7 6 -
a Tumor histological subtyping: +, well-differentiated; −, moderately or poorly differentiated.
-
b Immunohistochemistry: +, positive tumor staining; −, negative tumor staining.
-
c Univariate Wilcoxon rank test pooled over tumor stage.
-
- Table 3
Lung adenocarcinoma: predictive significance of each parameter
Tumor cell staining Covariates P Death from other causes Survivors Relapses Survival (mo) No. of patients Differentiationa + 4 25 31 36 ± 25 60 0.009 − 7 6 22 20.56 ± 22.69 35 Bcl-2b + 4 7 7 41.60 ± 28.91 18 0.009 − 10 14 53 27.60 ± 23.35 77 ABH antigensb + 6 6 17 33.19 ± 22.44 29 0.024 − 8 15 42 29.30 ± 26.09 65 p53b + 5 5 34 27.53 ± 24.30 44 0.076 − 9 16 25 32.50 ± 25.75 50 Pan-Rasb + 5 7 20 22.81 ± 18.11 32 0.43 − 9 14 39 23.85 ± 19.27 62 Ki-RAS mutations + 2 1 4 24.13 ± 18.85 12 0.34 − 12 20 56 18.56 ± 18.19 83 C-erbB2b + 2 4 6 35.05 ± 32.67 12 0.34 − 12 17 54 29.56 ± 23.80 83 Blood types O 6 7 24 23.09 ± 25.52 37 0.018 B 1 4 8 42.38 ± 28.03 13 0.32 A 5 6 27 31.58 ± 20.02 38 0.39 AB 2 3 1 33.17 ± 32.52 6 0.26 Sex Male 12 17 54 28.17 ± 24.36 83 0.0014 Female 2 4 6 44.69 ± 25.21 12 -
a Tumor histological subtyping: +, well-differentiated; −, moderately or poorly differentiated.
-
b Immunohistochemistry: +, positive tumor staining; −, negative tumor staining.
-
c Univariate Wilcoxon rank test pooled over tumor stage.
-
- Table 4
Lung adenocarcinoma: Cox proportional hazard models stratified on tumor staging
Covariates Univariate Cox model RR and 95% CI Selected multiple Cox models with interaction: RR and 95% CI A B C Differentiationa 0.41 (0.23–0.72) 0.33 (0.17–0.63) 0.41 (0.22–0.78) Bcl-2b 0.41 (0.18–0.90) 0.32 (0.14–0.74) 0.33 (1.13–0.79) A+ B+ H Antigensb 0.66 (0.37–1.19) 0.40 (0.21–0.77) p53b 1.75 (0.99–3.08) 4.56 (1.89–11)c 4.50 (1.89–10.7)c 0.50 (0.20–1.2)d 0.45 (0.18–1.13)d Blood group 1.54 (0.90–2.63) 3.01 (1.61–5.64) -
a Well-differentiated tumors.
-
b Positively stained tumor cells.
-
c Stages I and II.
-
d Stages III and IV.
-
Volume 6, Issue 3
